secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001104659-24-072044
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia receives FDA clearance for antibiotic-eluting bioenvelope EluPro for cardiac and neuromodulation devices
--------------------------------------------------------------------------------

- FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.
- Targets $600M US implantable electronic device protection market; no other biologic competitor currently.
- Delivers rifampin and minocycline embedded in extracellular matrix to reduce infection, migration, and erosion complications.
- Additional indications expand addressable market to neurostimulation/modulation, estimated at $8B worldwide.
- Elutia plans national CIED launch in H2 2024; adjacent neuro markets prioritized for expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924072044/0001104659-24-072044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924072044/tm2417396d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-072044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer